(Q34417093)

2 August 2017

1 reference

title

Economics of drug treatment: for which patients is it costeffective to lower cholesterol? (English)

1 reference

2 August 2017

B Jönsson

1

1 reference

PubMed ID

11675082

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

2 August 2017

1 reference

2 August 2017

358

1 reference

2 August 2017

1251-1256

1 reference

2 August 2017

9289

1 reference

Cardiovascular disease risk profiles.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

The Sheffield table for primary prevention of coronary heart disease: corrected

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Accounting for future costs in medical cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Editorial: Some reflections on cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

US and UK health economics: two disciplines separated by a common language?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Costs of coronary heart disease and stroke: the case of Sweden.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Methodology. Health-state utilities in a general population in relation to age, gender and socioeconomic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Stability of time-tradeoff utilities in survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906350-4

7 January 2021

10.1016/S0140-6736(01)06350-4

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11675082